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Abstract
Background: Triptans, specific symptomatic medications for migraine, are not effective in a proportion of patients, or
in all attacks, hence the importance of identifying predictors of response. Our aim was to investigate the association
between the efficacy of oral frovatriptan 2.5 mg and clinical characteristics of migraine attacks.
Methods: We enrolled 29 consecutive patients affected by migraine without aura at the Headache Center of
“Mondino” Institute of Pavia. Each patient was given a diary and asked to record prospectively the features of three
consecutive migraine attacks while using frovatriptan. A generalized estimating equations approach was used to deter-
mine phenotypic features associated with the pain free response at 2 hours.
Results: Participants provided complete data for 85 attacks. Thirty of these (34%) patients reported being pain free
2 hours after taking frovatriptan 2.5 mg intake. Unilateral pain, presence of phonophobia, presence of one or more
cranial autonomic symptoms and presence of one or more premonitory symptom were each associated with being pain
free at 2 hours.
Conclusions: The response to frovatriptan was associated with particular features of the migraine attack, either before
or during the pain phase of attacks. The data support larger studies to explore detailed attack phenotyping, with
particular attention to early signs, to enable individualized treatment in migraine.
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Introduction
Migraine has been identified as the second most dis-
abling disorder worldwide (1). Triptans, serotonin
5-HT1B/1D receptor agonists (2), provide the most effec-
tive symptomatic treatment for migraine, although
both efficacy and tolerability vary among molecules
within this class of drugs and between individuals,
including between attacks (3–6). The basis for this var-
iability remains to be determined.
Some attempts have been made to predict response,
with frustrating outcomes (7–12). Previous studies have
not included migraine premonitory symptoms, which
are increasingly the subject of recognition and study
(13). The potential predictive role of premonitory
symptoms would be relevant since these occur in the
early phase of the migraine attack, and would allow
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patients to treat at a point when triptans are known to
be much more effective, when pain is mild (14).
Moreover, some potential confounders that can
modify the response to a triptan, such as previous trip-
tan use or current use of preventive medication (5,15),
were not always accounted for in previous studies.
The aim of this study was to investigate prospective-
ly the association between different characteristics of
migraine attacks and the efficacy of frovatriptan in a
homogeneous population without potential confound-
ers to test the feasibility of deeper attack phenotyping
as an evolved approach to migraine treatment.
Methods
Between October 2012 and March 2014, we enrolled
consecutive patients who were seen at the Headache
Science Center of “C. Mondino” National
Neurological Institute of Pavia, Italy, for migraine
without aura. Included patients provided their written
informed consent and the study was approved by the
local Ethics Committee.
Inclusion/exclusion criteria
Participants were aged between 18 and 65 and affected
for at least 1 year with headache fulfilling ICHD-2 cri-
teria for migraine without aura (16), in use at the study
initiation, and no different for our cohort than ICHD-3
(17). Participants should have had a monthly attack
frequency between 1 and 5; the upper limit to avoid
an immediate consideration of initiating preventive
treatment.
Patients with diagnosis of medication overuse head-
ache at any time, current diagnosis of chronic migraine,
being unable to distinguish migraine from other types
of headache (i.e. tension-type headache) affecting them,
and patients suffering exclusively from migraine
attacks with onset at wakening were excluded from
participation. We excluded patients with migraine
with aura to avoid any confusion with the premonitory
phase. We also excluded patients with a contraindica-
tion to, or previous use of any triptan, use of opioids,
use of migraine preventive medication, and history of
psychiatric disorders.
Data collection
Consecutive patients diagnosed with migraine without
aura and prescribed frovatriptan 2.5 mg p.o. as acute
medication were included. They were provided with an
ad hoc headache diary and asked to record prospective-
ly the features of three consecutive migraine attacks.
Patients were instructed to use frovatriptan immediate-
ly after identifying a headache as a migraine attack
regardless of pain intensity, and excluding those with
an onset on wakening, and to fill their headache diary
when they used their medication.
The following characteristics of migraine attacks
were recorded: Location (unilateral), quality (pulsat-
ing) and intensity (on a four-point scale ranging from
3¼ severe pain to 0¼ absence of pain) of pain; presence
of the following symptoms: Nausea and/or vomiting;
photophobia, phonophobia, osmophobia, cranial allo-
dynia; cranial autonomic symptoms (CASs), including
eyelid oedema, forehead and facial sweating, conjunc-
tival injection and/or lacrimation, nasal congestion
and/or rhinorrhoea, miosis and/or ptosis; premonitory
symptoms of yawning, tiredness, mood changes, neck
stiffness, vertigo, nausea, photophobia, phonophobia,
osmophobia, food craving, thirst, problems with con-
centration, speaking or reading in the previous 24
hours; and time of frovatriptan intake from pain onset.
In order to assess cranial allodynia, patients were
asked if a non-painful stimulus, such as touching or
washing, produced pain on their face or head.
Pain intensity 2 hours after triptan intake and the
duration of the attack, marked by migraine symptom
resolution, were recorded in the diary. The efficacy of
frovatriptan was assessed as pain resolution within 2
hours after medication use (18). In case of pain persis-
tence at this time point, patients were allowed to use an
analgesic as rescue medication.
All patients were asked to return to the Headache
Centre either when they had managed to record three
consecutive attacks, or at the latest after 3 months from
the initial visit.
Data analysis
Given the aim of establishing predictability of response to
a triptan within individuals, the full analysis set was
defined as patients who took treatment on three attacks
and provided clinical data on each attack. Variables are
presented as mean SD, median with interquartile
range, or as frequency counts (%), as appropriate. To
examine the relationship between phenotypic variables
of the attack and the pain-free response to frovatriptan,
we used a single generalised estimating equations
approach with an unstructured correlation matrix. Pain
free at 2 hours was set as the binary dependent variable
and fitted with a logit link function (SPSS version 26,
IBM Statistics). The significance level was set atP< 0.05.
Results
Thirty-nine patients were enrolled. Ten patients failed
to record data for three attacks and were therefore
excluded from data evaluation. The remaining 29
patients successfully recorded the features of three con-
secutive migraine attacks whilst using frovatriptan 2.5
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mg, providing data for a total of 87 attacks. Data from
two attacks out of the 87 recorded were incomplete,
therefore the final dataset included 85 attacks.
Demographics and clinical features
Of the included patients, 83% were female (25/29),
mean standard deviation (range) age was 32.9 8.3
(19–47) years. Mean age at migraine onset was 21 11
(5–47) years, duration of illness 16.0 9.5 (1–30) years.
The frequency of attacks of migraine without aura per
month was 3 (median, IQR: 2–4). Prior to the study,
patients reported treating their migraine attacks with
either paracetamol or non-steroidal anti-inflammatory
drugs (NSAIDs). Twenty-seven patients exclusively
suffered from migraine without aura attacks, while
the remaining two patients reported infrequent epi-
sodes of tension-type headache and experienced one
tension-type attack each during the observation period.
Migraine attack features
The frequencies of the different attack features are
reported in Table 1. All attacks had duration shorter
than 72 hours. No patients reported symptoms of
migraine aura before or during the study.
Response to medication
Patients used frovatriptan after a mean period of 63
min following head pain onset. At this time, median
(IQR) pain intensity was 2 (1–3). At 2 hours, 35%
(30/85) of attacks were rendered pain free.
Modeling the clinical outcome at 2 hours after fro-
vatriptan intake: Unilateral pain (Wald v21¼ 11.44,
P¼ 0.001), presence of phonophobia (v21¼ 4.28,
P¼ 0.038), presence of one or more cranial autonomic
symptoms (v21¼ 8.42, P¼ 0.004) and presence of one
or more premonitory symptom (v24¼ 13.28, P¼ 0.010)
were each associated with a pain-free response.
Discussion
Our study suggests that deep phenotyping as a strategy
to develop personalized approaches to the acute treat-
ment of migraine is practical. Using the pain-free
response at 2 hours for frovatriptan 2.5 mg as the clin-
ical endpoint, unilateral pain, presence of phonopho-
bia, presence of one or more cranial autonomic
symptoms, and presence of one or more premonitory
symptom were each associated with that outcome.
Patients and physicians want better ways to associate
their treatments with outcomes and are largely unsatis-
fied with current prescription therapies (19,20). So far,
some studies have identified migraine features associat-
ed with (poor) triptan efficacy (7,8). Yet some of these
features – severe pain, nausea, vomiting – are typical of
the well-developed attack when triptans are less likely
to be effective (14). Indeed, the collection of a more
comprehensive set of migraine attack features, and
the subsequent analysis with respect to frovatriptan
response, suggest better prediction of outcomes is a
testable question.
Migraine premonitory symptoms have hitherto not
been used to predict clinical outcomes. Importantly,
our data across three attacks is consistent with an anal-
ysis across single attacks treated with sumatriptan 100
mg that found unilateral pain was a predictor of a pain-
free response at two hours (7).
We also found that the presence of CAS and unilat-
eral pain are predictors of good response to a triptan.
These findings are in line with two previous studies
where the presence of unilateral CAS predicted good
responses to sumatriptan (open study) (21) and riza-
triptan (randomized, double-blind, placebo-controlled
parallel-group trial) (22).
Table 1. Migraine characteristics of attacks (n¼ 85).
Migraine characteristics n (%)
Canonical attack symptoms
Unilateral pain 51 (60)
Pulsatile pain 35 (41)
Baseline pain intensity:
 Mild 30 (35)
 Moderate 40 (47)







Cranial allodynia 18 (21)
Cranial autonomic symptoms
(at least one) 16 (19)
Premonitory symptoms*
PS (at least one) 54 (63)
Tiredness 32 (37)
Neck stiffness 25 (29)







Mood changes 7 (8)
Food craving/thirst 1 (1)
Average onset prior to headache (min) 127 150
(range 10–720)
*In the last 24 hours.
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In contrast with our results, in an analysis of eletrip-
tan and sumatriptan studies, the presence of photopho-
bia in an attack predicted a poor response (8).
Moreover, other factors have been found to be associ-
ated to response to triptans, such as the presence of
nausea, vomiting, and pain severity (7,8).
Some of the varying outcomes across studies pre-
dicting treatment outcome are likely due to key
design differences. First, in some studies (7,8) patients
had to take their medication when pain was at least
moderate in intensity, whereas in the present study
patients were asked to use their medication immediate-
ly upon recognising their headache as a migraine
attack. Our advice to treat the attack early may have
prevented the complete phenotypic expression of the
attack, reducing the frequency of occurrence of some
features; that is, nausea, photophobia, or allodynia,
which were accordingly identified as being lower in
our patients than those reported in other studies
(23,24). However, the clinical relevance of early – as
compared to late – predictors of treatment response is
crucial, since standard clinical advice is to treat when
the patient recognises their attack. Secondly, although
previous studies were conducted on larger samples of
subjects, these did not minimize factors that may alter
the response to treatment, such as the use of preventive
medication, the previous use of triptans, or the exclu-
sion of attacks treated at waking (5,6,18). Thirdly, pre-
vious studies included patients suffering from both
migraine without or with aura (7,8,11,12), since there
are reported clinical differences (25). Moreover, a
recent analysis of data gathered from multiple rando-
mised trials found that the response to sumatriptan,
when used acutely in migraine attacks, was less effec-
tive in migraine with aura when compared to migraine
without aura (26).
Frovatriptan has been explored in a study showing
that current major depressive disorder was associated
with response to medication, while generalized anxiety
disorder, history of triptan intake, preventive medica-
tion and familiarity were not (12). However, despite
including medical history and socio-demographical
variables, this study investigated only six features of
migraine attacks, and used pain relief/absence within
4 hours after the intake of frovatriptan as an endpoint,
thus exposing results to a higher placebo effect rate as
compared to 2 hours pain free.
The presence of both CAS and unilateral pain can
represent an epiphenomenon of intense trigeminal
peripheral afferent activation, which may recruit
peripheral neurovascular 5-HT1B/1D receptors (27).
With respect to the presence of premonitory symptoms,
they suggest hypothalamic involvement, which is able
to facilitate the migrainous process resulting in the dis-
inhibition of the top-down modulation of the trigemi-
nal activity (28). Perhaps this activation through
hypothalamic mechanisms is important in terms of
the effect of a triptan.
Limitations
One important limitation of our study was the small
sample size. Our study aimed at screening a large set
of variables on a very well characterized and uncon-
founded population in order to identify the relevant
ones. As a feasibility study with the novelty of
exploring non-canonical migraine attack symptoms,
we sought to push the envelope with deeper pheno-
typing. Thus the number of participants was small
for the breadth of phenotyping. A much larger
study in terms of participants will be required to
clarify these questions. Another limitation of this
study design is that the complete phenotype of the
attacks may not have been expressed, as frovatriptan
was used early after pain onset. The frequency of
some features, such as nausea or photophobia, is
reported at lower rates compared to other studies,
accordingly (21).
In this study, we have shown with the use of a
prospective diary that unilateral pain, presence of
phonophobia, presence of one or more cranial auto-
nomic symptoms and presence of one or more pre-
monitory symptom were each associated with the
response to frovatriptan in this exploratory work.
All these features are manifest in the early phase of
the migraine, when the attack is more treatable by
triptans. The results support exploring larger studies
employing deep phenotyping to optimise acute
migraine treatment.
Clinical implications
• Unilateral pain, presence of phonophobia, presence of one or more cranial autonomic symptom and
presence of one or more premonitory symptom were each associated with a response to frovatriptan.
• Early identification of factors associated with a good triptan response would potentially offer a more
tailored strategy for treating acute migraine.
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